Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

Benzinga Newsdesk www.benzinga.com Positive 89.8%

Neg 0% Neu 0% Pos 89.8%

Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.